Acupuncture for the Postcholecystectomy Syndrome: A Systematic Review and Meta-Analysis

Zihan Yin,1,2 Qiwei Xiao,1,2 Guixing Xu,1,2 Ying Cheng,1 Han Yang,1,2 Jun Zhou,1,2 Yanan Fu,1,2 Jiao Chen,1,2 Ling Zhao,1,2 and Fanrong Liang1,2

1School of Acu-Mox and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
2Acupuncture Clinical Research Center of Sichuan Province, Chengdu, China

Correspondence should be addressed to Ling Zhao; zhaoling@cdutcm.edu.cn and Fanrong Liang; acuresearch@126.com

Received 13 March 2020; Revised 14 May 2020; Accepted 21 May 2020; Published 30 July 2020

Academic Editor: Adolfo Andrade-Cetto

Background. Postcholecystectomy syndrome (PCS) has become a common postoperative syndrome that requires systematic and comprehensive therapy to achieve adequate clinical control. Acupuncture and related therapies have shown clinical effects for PCS in many studies. However, systematic reviews/meta-analyses (SRs/MAs) for them are lacking. Objective. To evaluate the efficacy and safety of acupuncture in the treatment of PCS using randomized controlled trials (RCTs). Methods. Potentially eligible studies were searched in the following electronic databases up to 1 February 2020: PubMed, Embase, Cochrane Library, Web of Science (WoS), Chinese databases (Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), and China Science and Technology Journal Database (VIP)), and other sources (WHO ICTRP, ChiCTR, Clinical Trials, and Grey Literature Database). The RevMan 5.3 was employed for analyses. The Cochrane Collaboration’s risk of bias tool was used to assess the risk of bias (ROB). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the quality of the evidence. Results. A total of 14 RCTs with 1593 participants were included in this SR. MA showed that acupuncture in combination with conventional medicine (CM) did not show statistical differences in reduction in pain. However, acupuncture in combination with CM significantly reduced the incidence of postoperative nausea and vomiting (PONV) (RR, 0.71; 95% CI, 0.55–0.92) and improved gastrointestinal function recovery compared to the CM group. Acupuncture combined with traditional Chinese medicine and CM, and acupuncture as monotherapy may improve gastrointestinal function recovery with acceptable adverse events. Conclusion. Acupuncture may be an effective and safe treatment for PCS. However, this study lacks conclusive evidence due to poor quality evidence, limited data, and clinical heterogeneity of acupuncture methods in the included studies.

1. Introduction

Cholecystectomy is one of the surgical procedures commonly performed to treat gallbladder disease [1]. Previous studies indicate that there are approximately 700,000 cases of cholecystectomy performed each year [2]. Cholecystectomy may sometimes fail to relieve symptoms and may contribute to adverse events [3]. Postcholecystectomy syndrome (PCS) develops weeks to months after cholecystectomy and describes the presence of symptoms including abdominal pain, vomiting, and gastrointestinal symptoms [4–8]. Meanwhile, with the advent of the laparoscopic era, the number of cholecystectomy surges and the number of PCS patients may also increase [9]. The incidence of PCS has been reported to be at least 15%, and the onset of symptoms ranges from days to years [8, 10]. It seriously affects the quality of life of patients and also accelerates the deterioration of patients’ diseases; so, the demand for treatment is increasing.

PCS management is challenging due to the different etiology of PCS symptoms, hence requiring specific treatment strategies. Conservative treatment and surgical therapy are the widely used treatment modalities for PCS [9]. Surgical treatment is recommended when conservative treatment is ineffective and the risk of reoperation is higher than...
that for the initial operation. And conservative treatment is still generally recommended. In China, acupuncture therapy (AT), an ancient conservative therapy, plays an important role in the treatment of PCS [11]. In traditional Chinese medicine (TCM), AT is used to regulate disharmony of the organ system and is theoretically used to resolve symptoms by stimulating acupuncture points related to the organs [12–14]. Meanwhile, acupuncture is effective and safe for pain [15–17], postoperative nausea and vomiting (PONV) [18, 19], and gastrointestinal function [20, 21]. Based on the evidence, the acupuncture method may be safe and effective for PCS.

However, to the best of our knowledge, there are no reported systematic reviews and meta-analysis of randomized controlled trials (RCTs) examining the efficacy and safety of acupuncture for PCS. Therefore, this study is carried out to evaluate the current evidence on the efficacy and safety of acupuncture for PCS. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach [22] was used to assess the quality of evidence level. We hope to provide evidence for clinical applications and references for future scientific and clinical research.

2. Methods

This systematic review had been registered with PROSPERO under registration number CRD42019129287 and the protocol published [23]. The study was performed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [24] and A Measure Tool to Assess Systematic Reviews-2 (AMSTAR-2) [25].

2.1. Search Strategy. Two reviewers (QX and HY) independently conducted a comprehensive search on 4 English electronic databases (Web of Science, PubMed, Embase, and Cochrane Library), 4 Chinese electronic databases (Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), and China Science and Technology Journal Database (VIP)), and additional sources (Grey Literature Database, WHO ICTRP, Clinical Trials, and ChiCTR) from the inception date to 1 February 2020 for potentially eligible studies. Additional trials were identified from the list of all relevant publications. The included studies were all RCTs with no language restriction.

The following search terms were used: (1) clinical condition: postcholecystectomy syndrome, cholecystectomy, cholecystotomy, and cystectomy; (2) acupuncture terms: acupuncture therapy, acupuncture-moxibustion, meridian, electro-acupuncture, acupoint, acupuncture points, acupressure-acupuncture therapy, warm needling, moxa needle, acupuncture plus moxibustion, moxibustion with warming needle, auricular acupuncture, auricular needle, ear acupuncture, moxibustion, and abdomen acupuncture; and (3) study type (randomized controlled trial). We used “and” and “or” to connect the search terms. The search strategy for PubMed is shown in Table 1 as an example.

| Table 1: Search strategy for the PubMed database. |
|-----------------------------------------------|
| #1 postcholecystectomy syndrome[Title/Abstract] |
| #2 cholecystectomy[Title/Abstract]          |
| #3 cholecystotomy[Title/Abstract]          |
| #4 cystectomy[Title/Abstract]              |
| #5 #1 OR #2 OR #3 OR #4                    |
| #6 acupuncture therapy[Title/Abstract]    |
| #7 acupuncture-moxibustion[Title/Abstract] |
| #8 meridian"[Title/Abstract]              |
| #9 electro-acupuncture[Title/Abstract]    |
| #10 #6 OR #7 OR #8 OR #9                   |
| #11 acupoint[Title/Abstract]               |
| #12 acupuncture points[Title/Abstract]     |
| #13 acupressure[Title/Abstract]            |
| #14 acupuncture-acupuncture therapy[Title/Abstract] |
| #15 #11 OR #12 OR #13 OR #14               |
| #16 warm needling[Title/Abstract]          |
| #17 moxa needle[Title/Abstract]            |
| #18 acupuncture plus moxibustion[Title/Abstract] |
| #19 moxibustion with warming needle[Title/Abstract] |
| #20 #16 OR #17 OR #18 OR #19               |
| #21 auricular acupuncture[Title/Abstract] |
| #22 auricular needle[Title/Abstract]       |
| #23 ear acupuncture[Title/Abstract]        |
| #24 moxibustion[Title/Abstract]            |
| #25 #21 OR #22 OR #23 OR #24               |
| #26 abdom* acupuncture[Title/Abstract]    |
| #27 embedded thread therapy[Title/Abstract]|
| #28 embedding thread[Title/Abstract]       |
| #29 catgut embedding[Title/Abstract]       |
| #30 #26 OR #27 OR #28 OR #29              |
| #31 #10 OR #15 OR #20 OR #25 OR #30        |
| #32 #5 AND #31                            |
| #33 Postcholecystectomy Syndrome[MeSH Terms] |
| #34 Acupuncture therapy[MeSH Terms]       |
| #35 (#5 OR #33) AND #34                    |
| #36 #35 OR #32                            |
| #37 clinical[Title/Abstract]              |
| #38 trial[Title/Abstract]                 |
| #39 #37 AND #38                           |
| #40 clinical trials as topic[MeSH Terms]  |
| #41 clinical trial[Publication Type]       |
| #42 random*[Title/Abstract]               |
| #43 random allocation[MeSH Terms]         |
| #44 therapeutic use[MeSH Subheading]       |
| #45 #39 OR #40 OR #41 OR #42 OR #43 OR #44 |
| #46 #45 AND #36                           |

2.2. Inclusion and Exclusion Criteria

2.2.1. Type of Study. We included RCTs that evaluated the safety and efficacy of AT for PCS. Parallel and crossover studies were included. Nonrandomized clinical studies, quasi-RCTs, cluster RCTs, and case reports were excluded.

2.2.2. Types of Participants. We included patients with PCS above the age of 18 years, regardless of race, gender, and region. We considered actual clinical conditions; however, there were no exact diagnostic criteria for PCS, but the diagnosis was confirmed based on surgery history and associated symptoms (pain, PONV, and gastrointestinal symptoms).
2.2.3. Types of Interventions. We included studies in which different types of acupuncture (manual acupuncture (MA), electronic acupuncture (EA), acupuncture-moxibustion (AM), and similar) were used in the intervention group, regardless of the treatment duration and frequency. The control group included no treatment group, placebo group, pharmacological therapy, and other conventional medicine (CM) groups.

2.2.4. Types of Outcome Measures. (1) Primary Outcomes. Pain intensity (the results measured were converted to the 11-point Numerical Rating Scale) [26] and PONV incidence [27] were analyzed.

(2) Secondary Outcomes. (1) The recovery of gastrointestinal function (first defecation time, first flatus time, and first bowel sound time) [28]. (2) Adverse effects (relevant symptoms caused by acupuncture).

2.3. Study Selection and Data Extraction. All reviewers had previous professional training on study selection and data extraction. After the elimination of duplicate studies and uploading of eligible RCTs into NoteExpress, two researchers (QX and HY) independently screened the titles, abstracts, and keywords to identify studies that potentially met the inclusion criteria. Disagreements were resolved through a discussion between the two researchers. However, if the discussion did not resolve the disagreement, a third researcher (LZ or FL) was consulted to assist in making the final decision. Details of the selection procedure for studies are shown in a PRISMA flowchart (Figure 1).

Data extraction was independently conducted by two authors (QX and HY) using standardized tabulation. The extracted information included the first author, publication date, country, sample size, mean age, gender, details of the treatment group and control group, outcome, conclusion, and acupuncture details. In case of a disagreement, a 3rd party’s opinion was sought to assist in making the final decision. The primary authors were contacted if any missing or additional information was needed.

2.4. Quality Assessment. Two authors (ZY and GX) independently assessed the risk of bias (ROB) of the included studies using the Cochrane Handbook for Systematic Reviews of Interventions [29, 30]. The following 7 items were assessed: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. Each item was evaluated and categorized as "low risk," "unclear," and "high risk." The arbiter (FL) solved any disagreement between the two reviewers.

2.5. Statistical Analysis. We used endpoint scores or prepost differences as outcome measures for each included study. Review Manager (RevMan) Version 5.3 software (Cochrane, London, UK) suggested by Cochrane Collaboration was used for quantitative synthesis. For the meta-analyses, the fixed-effects model by the Mantel–Haenszel method was used; otherwise, the random-effects model adopted by the DerSimonian–Laired method was used. The I² statistic was used to measure the heterogeneity among the studies. We considered that there was no heterogeneity when p > 0.1 and I² < 50%, and all data were analyzed with 95% CIs. The dichotomous data were analyzed by risk ratios (RR), while for continuous data, the standard mean differences (SMD) were used. The subgroup was adopted on the condition of high data heterogeneity. Funnel plots were used to measure publication bias when the number of included studies was more than 10. If the funnel chart was evenly distributed, there was no reporting of bias.

2.6. Quality of Evidence. The GRADE approach [22] was used by the reviewers to assess the quality of evidence of the obtained outcome indicators from five items of research limitations, inconsistency, indirectness, accuracy, and publication bias. The quality of evidence was rated as “very low,” “low,” “moderate,” or “high” based on GRADE rating standards. The quality of the evidence “high” indicates that future research is very unlikely to change existing evidence; “moderate” indicates that future research may change the results; being “low” level indicates that future research is likely to have an important impact on existing evidence and is likely to change the evaluation results; and “very low” indicates that we are highly uncertain about the existing evidence.

3. Results

3.1. Study Description

3.1.1. Literature Search. In the initial stage of selection, 162 Chinese studies and 39 English studies were collected, and 16 data were obtained from other sources. After excluding 125 duplicate literatures, 92 RCTs remained. By the end of initial screening, there were 19 studies left. Finally, 5 studies were excluded (2 non-RCT and 3 nonacupuncture) and 14 studies remained [31–44]. The PRISMA flowchart is shown in Figure 1, and full-text articles excluded with reasons are covered in Appendix B.

3.1.2. Study Characteristics. Table 2 presents the characteristics of the included RCTs. Among the 14 [31–44] included RCTs, 1 [31] was in Turkish and 13 [32–44] were in Chinese. The RCTs were published from 2006 to 2019, and they were reported in full-texts. All patients were adults (age > 18 years old). A total of 14 RCTs with 1593 participants, 870 in the intervention group and 723 in the control group, were included in this systematic review and meta-analysis. Experimental interventions included manual acupuncture (MA), acupuncture-moxibustion (AM), and electroacupuncture (EA). The control groups received conventional medicine (CM), which included conventional nutrition rehydration and anti-infective agents, while some studies reported the use of tramadol [31], cisapride [34], ondansetron [37], metoclopramide [39], morphine [41, 43],
3.1.3. Acupuncture Details. MA was reported in most studies [31, 35, 37, 39, 40, 42, 43], EA was used in 5 studies [32, 33, 36, 41, 42], and AM was used in 2 studies [34, 38]. Zu San Li (ST36) [32–44] was the most frequently used acupoints, while Nei Guan (PC6) [31, 32, 34–39, 43] was reported to be used in 9 trials. The reported insertion depth was 0.25 mm–40 mm, and the penetration depth varied widely due to the use of different acupoints. A total of 9 studies [31, 34–39, 42, 44] were exposed to deqi, and the 9 RCTs [31, 32, 36, 37, 39–42, 44] reported needle stimulation. The most commonly used needle retention time was 30 minutes; the most frequent number of treatment sessions was 3; and the most commonly used duration and frequency of AT treatment was 72 hours and 1–2 times/day. Details of the acupuncture therapies used are shown in Table 3.

3.2. Quality Assessment. All the 14 trials included were described as RCTs. We measured the ROB by Cochrane Handbook V.5.3.0. The use of random sequence generation was reported in 7 studies [31, 32, 35, 36, 40–42], out of which one RCT [33] had “high risk,” and the descriptions in 6 [34, 37–39, 43, 44] studies were unclear; allocation concealment was assessed as being “low risk” in 1 study [40],
| Study (reference) | Country | Sample size (A)/ (B) | Mean age (A)/ (B) | Gender (M : F) (A)/(B) | (A) Treatment group | (B) Control group | Acupoints | Outcomes | Primary outcomes | Secondary outcomes | Conclusion (+/−) |
|------------------|---------|---------------------|------------------|------------------------|---------------------|-------------------|------------|---------|------------------|-------------------|------------------|
| Erden et al., 2017 [31] | Turkey | 31/29 | 46.77/45.64 | A: (6 : 25) B: (3 : 25) | MA (B) | CM (tramadol) | Ri Yue (GB24), Yang Ling Quan (GB34), Guang Ming (GB37), di Wu Hui (GB42), Xing Jian (LR2), Nei Gu (PC6), He Gu (LH) | Postoperative pain scores (NRS) | (1) Postoperative satisfaction index (2) Analgesic consumption | Despite detection of a reduction in postoperative pain scores, the application of acupuncture did not cause any change in the consumption of tramadol (+) |
| Chang et al., 2019 [32] | China | 45/45 | (39.72 ± 5.08)/ (39.41 ± 5.25) | A: (31 : 14) B: (28 : 17) | EA (B) | CM | San Yin Jiao (SP6), Nei Guan (PC6), Zu san Li (ST37) | The recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time) | (1) Visual analogue rating of nausea (2) Ventriculin | Electroacupuncture can promote postoperative recovery of patients with laparoscopic cholecystectomy and regulate gastric peristalsis (+) |
| Cui 2006 [33] | China | 275/112 | 39.6/40.5 | A: (85 : 190)cB: (23 : 89) | EA + TCM (B) | CM | Zu san Li (ST38) | The recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time) | — | Acupuncture and traditional Chinese medicine can promote postoperative recovery of patients with laparoscopic cholecystectomy (+) |
| Xiaoqian 2018 [34] | China | 50/50 | (50.5 ± 7.0)/ (50.3 ± 5.0) | A: (40 : 60) | AM (B) | CM (cisapride) | Zhong Wan (RN12), Dan shu (BL19), Gan shu (BL18), Nei Guan (PC6), Zu san Li (ST36) | The clinical curative effect | (1) The recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time) | (2) PONV | MA can promote recovery of gastrointestinal function after cystic resection adjustment (+) |
| Shangbo 2016 [35] | China | 30/30 | (46.27 ± 6.39)/ (45.72 ± 6.18) | A: (17 : 13) B: (14 : 16) | MA (B) | CM | Gong sun (SP4), shang Ju Xu (ST37), Nei Guan (PC6), Zu san Li (ST36) | Postoperative pain scores | (1) The recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time) | (2) Ventriculin (GAS) (3) PONV | For patients undergoing cholecystectomy, acupuncture on the basis of CM therapy can achieve better efficacy than CM of patients (+) |
| Study            | Country | Patients | Age (Mean ± SD) | Group | Treatment | Postoperative pain scores | Recovery of gastrointestinal function | Adverse events |
|------------------|---------|----------|----------------|-------|-----------|---------------------------|----------------------------------------|---------------|
| Hui 2018         | China   | 76/76    | (37.6 ± 5.1) / (35.8 ± 8.5) | A: (41: 35) B: (39: 37) | EA + auricular therapy + (B) CM | Postoperative pain scores | The recovery of gastrointestinal function (first flatus time and 1st bowel sounds time) | Electroacupuncture combined with auricular therapy can significantly improve the recovery of patients after laparoscopic cholecystectomy (+) |
| Liu and Zhang 2013 | China   | 55/55    | (51.4 ± 10.2) / (50.6 ± 9.7) | A: (16: 39) B: (18: 37) | CM (ondansetron) | PONV | The recovery of gastrointestinal function (first flatus time and 1st bowel sounds time) | Acupuncture is efficacy and safe in treating vomiting after laparoscopic cholecystectomy (+) |
| Shen 2017        | China   | 37/37    | 49.3           | (26: 48) | AM + TCM + (B) CM | Postoperative pain scores | The clinical curative effect | After cholecystectomy, acupuncture combined with traditional Chinese medicine can shorten the recovery time of gastrointestinal function and reduce the incidence of adverse reactions (+) |
| Shen 2014        | China   | 57/57    | (36.5 ± 12.7) / (35.0 ± 11.3) | A: (26: 31) B: (25: 32) | CM (metoclopramide) | Postoperative pain scores | The recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time) | Metoclopramide and acupuncture are effective in treating PONV with minor adverse reaction (+) |
| Jing 2017        | China   | 40/40    | (47.23 ± 11.68) / (48.12 ± 14.47) | A: (17: 23) B: (17: 23) | CM | Postoperative pain scores | The recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time) | Acupuncture is efficacy and safe in treating the recovery of gastrointestinal function after laparoscopic cholecystectomy (+) |
| Study             | Country | Subjects | Age Range | A: B | Method | Acupuncture Points | Outcome Measures                                                                 | Notes                                                                 |
|-------------------|---------|----------|-----------|------|--------|--------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Wang 2016 [41]    | China   | 30/30    | (53.50 ± 8.30)/(51.30 ± 8.10) | A: (13: 17) B: (14: 16) | EA     | CM (morphine)      | Zu san Li (ST37), Tai Chong (ST23), Yang Ling Quan (GB34)                         | Pain intensity, the nausea incidence and the vomiting incidence       |
|                   |         |          |           |      |        |                    | The recovery of gastrointestinal function (first defeation time and 1st flatus time) | Electroacupuncture could effectively relieve postoperative pain and promote the recovery of gastrointestinal function after operation, which reduced the incidence of PONV without excessive sedation (+) |
| Xiaobing and Jiahe 2018 [42] | China   | 52/52    | (55.23 ± 3.4)/(56.37 ± 3.1) | A: (30: 22) B: (24: 28) | MA + (B) | CM                 | Zu san Li (ST37), Xia Wan (RN10), Zhong Wan (RN12), Guan Yuan (RN4), Hua Rou Men (ST24), Qi Hai (RN6), Yang Ling Quan (GB34), He Gu (LI4), Zu san Li (ST38), san Yin Jiao (SP6), Nei Guan (PC6), Dan Nang (EX-LE6), A shi point | The clinical effective (1) The recovery of gastrointestinal function (first defeation time and 1st flatus time) (2) Venticulin (MMP-9, TIMP-1) (3) Quality of life Moxibustion and combined with MA for postoperative gastrointestinal function in patients with laparoscopic cholecystectomy has good therapeutic significance (+) |
| Xiao 2012 [43]    | China   | 60/60    | 18–78     | A: (44: 16) B: (40: 20) | MA     | CM (fentanyl and morphine) | Postoperative pain scores                                                      | Acupuncture is effective in the analgesia after laparoscopic cholecystectomy and has fewer adverse reactions such as the digestive tract (+) |
| Yang and Liu 2008 [44] | China   | 32/30    | (68.59 ± 2.44)/(69.97 ± 1.59) | A: (11: 21) B: (8: 22) | EA + (B) | CM                 | Zu san Li (ST38), san Yin Jiao (SP6)                                           | The treatment of acupuncture can accelerate the recovery of gastrointestinal function in patients after laparoscopic cholecystectomy (+) |
while other [31–39, 41–44] RCTs did not report allocation concealment; no study mentioned blinding of participants and outcome assessors; all studies [31–44] indicated that the outcome data were complete and were assessed as "low risk;" in selective outcome reporting, 11 studies [31–36, 39–42, 44] were assessed as "low risk" and 3 RCTs [37, 38, 43] were assessed as "unclear" due to lack of sufficient information; and in the bias category, 9 studies [31, 32, 34, 36, 37, 40–42, 44] were ranked to be at "low risk" and 5 RCTs [33, 35, 38, 39, 43] were judged as "unclear" due to lack of adequate information. Figure 2 presents a summary of the ROB for each included study.

3.3. Effects of Intervention. The summaries for all comparison results and GRADE analyses are shown in Table 4. There was great heterogeneity, and we had performed a subgroup analysis based on the type of acupuncture.

3.3.1. Reduction in Pain Intensity. Based on the existing strong correlation between the pain assessment scales, the visual analogue scale (VAS), or other scales, results were all converted to the 11-point digital rating scale (0 points for no pain, and 10 points for the most severe pain) [45].

(1) AT + CM versus CM. There were no statistical differences reported between AT + CM and CM results (n = 272; SMD, 1.33; 95% CI, −0.78 to 3.43; p = 0.22; heterogeneity: $X^2 = 99.23$, $p < 0.00001$, $I^2 = 98\%$). In subgroup analyses, MA + CM and CM showed no statistically significant differences (n = 100; SMD, 0.46; 95% CI, −1.44 to 1.37; $p = 0.63$; Figure 3(a)). EA + auricular therapy + CM and CM showed statistically significant differences (n = 152; SMD, 1.33; 95% CI, −0.78 to 3.43; $p < 0.00001$; Figure 3(a)). Erden et al. [31] used CM and tramadol and reported no statistically significant difference between AT + CM with tramadol and CM with tramadol (n = 60; SMD, −0.50; 95% CI, −1.02 to 0.01; $p = 0.06$). The study further reported that the application of acupuncture did not cause any change in the consumption of tramadol. We carried out sensitivity analysis, and the study was excluded and the meta-analysis repeated. The results indicated that there was a significant difference between AT + CM and CM (n = 212; SMD, 2.25; 95% CI, 0.68–3.82; $p < 0.005$). The quality of evidence for the outcome was "low."

(2) AT versus CM. There was no significant difference between AT and CM (n = 60; SMD, −0.21; 95% CI −0.72 to 0.30; $p = 0.42$; Figure 3(b)). Wang [41] reported that there was no significant difference between acupuncture and CM combined with morphine. The quality of evidence for this outcome was "moderate."

3.3.2. POVN Incidence. The POVN effect is defined as the ratio of the number of people showing POVN after treatment to the total number of people in the treatment group.

(1) AT + CM versus CM. Statistically significant difference was reported in POVN between AT plus CM and CM (n = 312; RR, 0.71; 95% CI, 0.55 to 0.92; $p = 0.01$; heterogeneity: $X^2 = 0.29$, $p = 0.87$, $I^2 = 0\%$; Figure 4(a)). Subgroup analyses revealed that AM + CM and CM showed no

### Table 3: Details of acupuncture treatment methods.

| Study (reference) | Depth of insertion | Deqi | Needle stimulation | Needle retention duration | Number of treatment sessions | Frequency of treatment | Duration |
|-------------------|-------------------|------|---------------------|---------------------------|-----------------------------|------------------------|----------|
| Erden et al., 2017 [31] | 0.25–0.3 mm | Y    | Twirling every 10 min | 30 min | 6 | 0, 1\textsuperscript{st}, 2\textsuperscript{nd}, 6\textsuperscript{th}, and 12\textsuperscript{th}, and 18\textsuperscript{th} | 18 h |
| Chang et al., 2019 [32] | NR | NR | Electrical stimulation (30 times per minute) | 20 min | NR | 1 time every 4 hours | NR |
| Cui 2006 [33] | NR | NR | NR | 20 min | 4 | 2 times every day | 48 h |
| Xiaojian 2018 [34] | 20–30 mm | Y    | NR | 30 min | 28 | 1 time every day | 4 w |
| Erden et al., 2017 [31] | 25–32.5 mm | Y    | Electrical stimulation (4–20 HZ) | 30 min | 4 | 2 times every day | 48 h |
| Hui 2017 [36] | NR | Y | Twirling 1-2 times per 30 min | 20–30 min | 3 | 1 time every day | 72 h |
| Liu and Zhang 2013 [37] | 7.5–40 mm | Y    | Electrical stimulation (4–20 HZ) | 30 min | 3 | 1 time every day | 72 h |
| Shen 2017 [38] | NR | Y | NR | 20–30 min | 3–6 | 1–2 times every day | 72 h |
| Shen 2014 [39] | 7.5–40 mm | Y    | Electrical stimulation (10 HZ) | 30 min | <5 | 1 time every day | <120 h |
| Jing 2017 [40] | NR | NR | NR | 30 min | 2 | 2 times every day | 24 h |
| Wang 2016 [41] | 40 mm | NR | Electrical stimulation (2 HZ) | 30 min | NR | NR | 4 w |
| Xiao and Jiahe 2018 [42] | 40 mm | Y | Twirling every 30 min | 30 min | NR | NR | 4 w |
| Xiao 2012 [43] | NR | NR | NR | 10–15 min | 9 | 3 times every day | 72 h |
| Yang and Liu 2008 [44] | NR | Y | Electrical stimulation (30 times per minute) | 20 min | NR | 1 time every 4 hours | NR |

Notes: NR: not recorded; Y: yes.
significant differences ($n = 100$; RR, 0.74; 95% CI, 0.53 to 1.03; $p = 0.07$; Figure 4(a)); MA + CM and CM had no statistically significant differences ($n = 60$; RR, 0.75; 95% CI, 0.48 to 1.16; $p = 0.20$; Figure 4(a)); and EA + auricular therapy + CM and CM had no statistically significant differences ($n = 152$; RR, 0.60; 95% CI, 0.28 to 1.29; $p = 0.19$; Figure 4(a)). The quality of the evidence shown was "moderate."

(2) **AT versus CM.** There was no significant difference between AT and CM ($n = 170$; RR, 0.82; 95% CI, 0.60 to 1.12; $p = 0.22$; Figure 4(b)). The quality of evidence for the outcome was "moderate."

(3) **AT + TCM + CM versus CM.** There was no statistically significant difference between AT + TCM + CM and CM ($n = 74$; RR, 0.5; 95% CI, 0.05 to 5.28; $p = 0.58$; Figure 4(c)). The quality of evidence was "very low."

### 3.3.3. The Recovery of Gastrointestinal Function

(1) **First Defecation Time.** **AT + CM versus CM:** there was a statistically significant difference reported in first defecation time between AT plus CM and CM ($n = 244$; SMD, −2.05; 95% CI, −2.39 to −1.72; $p < 0.00001$; heterogeneity: $X^2 = 62.61, p < 0.00001, I^2 = 97%$; Figure 5(a)). The quality of evidence for the outcome was "moderate." **AT versus CM:** there was statistically significant difference between AT and CM ($n = 60$; SMD, −1.64; 95% CI, −2.24 to −1.05; $p < 0.00001$; Figure 5(b)). The quality of evidence was "moderate." **AT + TCM + CM versus CM:** there was a statistically significant difference between AT + TCM + CM and CM ($n = 387$; SMD, −1.03; 95% CI, −1.26 to −0.79; $p < 0.00001$; Figure 5(c)). The quality of evidence for the outcome was "low."
Table 4: Quality of evidence included RCTs by GRADE.

| Interventions          | Included RCTs (patients) | Relative effect (95% CI) | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Quality of evidence |
|------------------------|--------------------------|--------------------------|--------------|---------------|--------------|-------------|------------------|---------------------|
| **Reducing pain intensity** |                          |                          |              |               |              |             |                  |                     |
| AT + CM                | 3 (272)                  | SMD 1.33 (−0.78 to 3.43) | −1①          | −1②          | 0            | 0           | 0                | Low                 |
| AT                     | 1 (60)                   | SMD −0.21 (−0.72 to 0.30) | 0            | 0             | 0            | 0           | 0                | Moderate            |
| PNV                    |                          |                          |              |               |              |             |                  |                     |
| AT + CM                | 3 (312)                  | RR 0.71 (0.55 to 0.92)   | −1①          | 0             | 0            | 0           | 0                | Moderate            |
| AT                     | 2 (170)                  | RR 0.82 (0.60 to 1.12)   | −1①          | 0             | 0            | 0           | 0                | Moderate            |
| AT + TCM + CM          | 1 (74)                   | RR 0.50 (0.05 to 5.28)   | −1①          | 0             | 0            | 0           | −1②              | Very low            |
| **First defecation time** |                          |                          |              |               |              |             |                  |                     |
| AT + CM                | 3 (244)                  | SMD −2.05 (−2.39 to −1.72) | 0           | −1②          | 0            | 0           | 0                | Moderate            |
| AT                     | 1 (60)                   | SMD −1.64 (−2.24 to −1.05) | 0           | 0             | 0            | −1②        | 0                | Moderate            |
| AT + TCM + CM          | 1 (387)                  | SMD −1.03 (−1.26 to −0.79) | −1①          | 0             | 0            | 0           | −1②              | Low                 |
| **First flatus time**  |                          |                          |              |               |              |             |                  |                     |
| AT + CM                | 7 (648)                  | SMD −2.66 (−3.82 to −1.50) | −1①          | −1②          | 0            | 0           | 0                | Low                 |
| AT                     | 1 (60)                   | SMD −0.69 (−1.21 to −0.17) | 0           | 0             | 0            | −1②        | 0                | Moderate            |
| AT + TCM + CM          | 2 (461)                  | SMD −2.07 (−2.31 to −1.83) | −1①          | 0             | 0            | 0           | −1②              | Low                 |
| **First bowel sounds time** |                          |                          |              |               |              |             |                  |                     |
| AT + CM                | 4 (402)                  | SMD −2.85 (−3.15 to −2.55) | −1①          | −1②          | 0            | 0           | 0                | Low                 |
| AT + TCM + CM          | 2 (461)                  | SMD −2.91 (−3.19 to −2.64) | −1①          | 0             | 0            | 0           | −1②              | Low                 |

Notes: ①Most information is from the moderate risk studies, and there are major limitations. ②The size and direction of the effect size, the overlap of the confidence interval is small, the p value of the heterogeneity test is small, and the combined results of I² value are large. ③The sample is insufficient. ④Few studies are included, and there may be a large publication bias.

(2) First Flatus Time. AT + CM versus CM: a statistically significant difference was shown in first defecation time between AT plus CM and CM (n = 468; SMD, −2.66; 95% CI, −3.82 to −1.50; p < 0.00001; heterogeneity: X² = 184.22, p < 0.00001, I² = 97%; Figure 6(a)). Subgroup analyses revealed that EA + CM and CM showed statistically significant differences (n = 152; SMD, −0.87; 95% CI, −1.20 to −0.54; p < 0.00001; heterogeneity: X² = 0.06, p = 0.80, I² = 0%; Figure 6(a)); MA + CM and CM had statistically significant differences (n = 244; SMD, −3.40; 95% CI, −5.92 to −0.88; p = 0.008; heterogeneity: X² = 86.42, p < 0.00001, I² = 98%; Figure 6(a)); AM + CM and CM showed statistically significant differences (n = 100; SMD, −3.70; 95% CI, −4.35 to −3.04; p < 0.00001; Figure 6(a)); and EA + auricular therapy + CM and CM showed statistically significant differences (n = 152; SMD, −3.33; 95% CI, −3.83 to −2.84; p < 0.00001; Figure 6(a)). The quality of evidence for the outcome was “low.” AT versus CM: there were significant differences between AT and CM (n = 60; SMD, −0.69; 95% CI, −1.21 to −0.17; p = 0.01; Figure 6(b)). The quality of evidence for the outcome was “moderate.” AT + TCM + CM versus CM: there were significant differences between AT + TCM + CM and CM (n = 461; SMD, −2.07; 95% CI, −3.15 to −0.9); p < 0.00001; heterogeneity: X² = 0.57, p = 0.45, I² = 0%; Figure 6(c)). Subgroup analyses revealed that EA + TCM + CM and CM showed significant differences (n = 387; SMD, −2.03; 95% CI, −2.29 to −1.77; p < 0.00001; Figure 6(c)), and AM + TCM + CM and CM showed significant differences (n = 74; SMD, −2.28; 95% CI, −2.87 to −1.69; p < 0.00001; Figure 6(c)). The quality of evidence for the outcome was “low.”

(3) First Bowel Sounds Time. AT + CM versus CM: significant differences were reported between AT + CM and CM (n = 402; SMD, −2.85; 95% CI, −3.15 to −2.55; p < 0.00001; heterogeneity: X² = 106.25, p < 0.00001, I² = 97%; Figure 7(a)). Subgroup analyses showed that EA + CM and CM had significant differences (n = 90; SMD, −1.16; 95% CI, −1.61 to −0.71; p < 0.00001; Figure 7(a)); MA + CM and CM had significant differences (n = 60; SMD, −3.77; 95% CI, −4.63 to −2.91; p < 0.00001; Figure 7(a)); AM + CM and CM had significant differences (n = 100; SMD, −3.82; 95% CI,
1.1.1 MA + CM VS CM

Test for overall effect:

Heterogeneity: not applicable

Study or subgroup AT + CM

SDMean Total
CM
SDMean Total
Weight
(%)
Std. Mean difference
IV, random, 95% CI

Subtotal (95% CI)
61 59 66.5
0.46 [−1.44, 2.37]

Test for overall effect: Z = 0.48 (P = 0.63)

1.1.2 EA + Auricular therapy + CM VS CM

Subtotal (95% CI) 61 59

Heterogeneity: not applicable

Test for overall effect: Z = 0.22 (P = 0.82)

Test for subgroup differences: chi² = 3.04 (P = 0.08)

Total (95% CI) 137 135

Test for overall effect: Z = 1.24 (P = 0.22)

Heterogeneity: not applicable

Test for subgroup differences: chi² = 3.39; chi² = 99.23; df = 2 (P < 0.0001); I² = 98%

Total (95% CI) 100.0 1.33 [−0.78, 3.43]

Figure 3: Forest plot of reduction in pain intensity: (a) AT + CM vs. CM and (b) AT vs. CM.

3.4. Safety. A total of 4 RCTs with 424 participants [37–40, 43] provided information on adverse events associated with acupuncture (Table 5). One trial [40] reported that no adverse events occurred during the interventions, and adverse events were reported in the other 3 studies. Only 2 events [39, 43] reported dizziness during acupuncture. A total of three studies [37, 38, 43] reported that CM could cause dizziness, constipation, extrapyramidal symptoms, PONV, and hypotension. However, based on other existing studies, acupuncture was safe for PCS. Table 5 presents the details of the adverse events.

3.5. Heterogeneity. Acupuncture methods, techniques, acupoints, depth of insertion, acupuncture doses, acupuncture operators, acupuncture retention duration, and treatment sessions among other factors were varied, which may lead to high clinical heterogeneity; hence, subgroup analysis was performed. Meanwhile, medication therapy showed heterogeneity on accounts of different types of drugs and dosages. However, since most of the studies did not provide adequate CM information, we did not accomplish the subgroup analyses. Finally, we found that the subgroup according to the type of acupuncture could better illustrate the heterogeneity. And we also tried to perform sensitivity analysis by excluding studies that were “high risk,” however, very few articles were included leading to high risk of bias.

3.6. Reporting Bias. Since the number of included studies did not exceed 10, funnel plots were not used to measure publication bias.

3.7. Quality of Evidence. The GRADE approach was used to evaluate the quality of the evidence of the included studies, and the analyses are presented in Table 4. Outcomes were the reduction in pain intensity, PONV incidence, 1st defecation time, 1st flatus time, and 1st bowel sounds time. A total of 13 outcomes were applied to the RCTs. The quality of the evidence for the overall outcomes was acceptable. The results showed that there was 1 (1/13, 7.7%) outcome with very low quality evidence, 6 (6/13, 46.15%) with low quality evidence, 3 (6/13, 46.15%) with moderate quality evidence, and none with high quality evidence. However, it is difficult for therapists and patients to use blinding for acupuncture.
| Study or subgroup | AT + CM | Events | Total | CM | Events | Total | Weight (%) | Risk ratio M-H, fixed, 95% CI | Risk ratio M-H, fixed, 95% CI |
|------------------|---------|--------|-------|----|--------|-------|------------|-------------------------------|-------------------------------|
| **2.1.1 AM + CM VS CM** |         |        |       |    |        |       |            |                               |                               |
| Hou et al, 2018  | 25      | 50     | 34    | 50 | 49.3   | 0.74  | [0.53, 1.03] |                               |                               |
| **Subtotal (95% CI)** | 25      | 50     | 34    | 50 | 49.3   | 0.74  | [0.53, 1.03] |                               |                               |
| **Total events** | 25      | 34     |       |    |        |       |            |                               |                               |
| Heterogeneity: not applicable |   |        |       |    |        |       |            |                               |                               |
| Test for overall effect: Z = 1.79 (P = 0.07) |   |        |       |    |        |       |            |                               |                               |
| **2.1.2 MA + CM VS CM** |         |        |       |    |        |       |            |                               |                               |
| Hua 2016         | 15      | 30     | 20    | 30 | 29.0   | 0.75  | [0.48, 1.16] |                               |                               |
| **Subtotal (95% CI)** | 15      | 30     | 20    | 30 | 29.0   | 0.75  | [0.48, 1.16] |                               |                               |
| **Total events** | 15      | 20     |       |    |        |       |            |                               |                               |
| Heterogeneity: not applicable |   |        |       |    |        |       |            |                               |                               |
| Test for overall effect: Z = 1.29 (P = 0.20) |   |        |       |    |        |       |            |                               |                               |
| **2.1.3 EA + Auricular therapy + CM VS CM** |         |        |       |    |        |       |            |                               |                               |
| Liu et al, 2018  | 9       | 76     | 15    | 76 | 21.7   | 0.60  | [0.28, 1.29] |                               |                               |
| **Subtotal (95% CI)** | 9       | 76     | 15    | 76 | 21.7   | 0.60  | [0.28, 1.29] |                               |                               |
| **Total events** | 9       | 15     |       |    |        |       |            |                               |                               |
| Heterogeneity: not applicable |   |        |       |    |        |       |            |                               |                               |
| Test for overall effect: Z = 1.31 (P = 0.19) |   |        |       |    |        |       |            |                               |                               |

Total events: 156

Heterogeneity: ch² = 0.29, df = 2 (P = 0.87); I² = 0%

Test for overall effect: Z = 2.56 (P = 0.01)

Test for subgroup differences: ch² = 0.27, df = 2 (P = 0.88); I² = 0%

(a)

| Study or subgroup | AT + CM | Events | Total | CM | Events | Total | Weight (%) | Risk ratio M-H, fixed, 95% CI | Risk ratio M-H, fixed, 95% CI |
|------------------|---------|--------|-------|----|--------|-------|------------|-------------------------------|-------------------------------|
| **2.2.1 EA VS CM (Morphine)** |         |        |       |    |        |       |            |                               |                               |
| Wang et al, 2016 | 9       | 30     | 15    | 30 | 33.3   | 0.60  | [0.31, 1.15] |                               |                               |
| **Subtotal (95% CI)** | 9       | 30     | 15    | 30 | 33.3   | 0.60  | [0.31, 1.15] |                               |                               |
| **Total events** | 9       | 15     |       |    |        |       |            |                               |                               |
| Heterogeneity: not applicable |   |        |       |    |        |       |            |                               |                               |
| Test for overall effect: Z = 1.53 (P = 0.13) |   |        |       |    |        |       |            |                               |                               |
| **2.2.2 MA VS CM (Ondansetron)** |         |        |       |    |        |       |            |                               |                               |
| Liu et al, 2013  | 28      | 55     | 30    | 55 | 66.7   | 0.93  | [0.65, 1.33] |                               |                               |
| **Subtotal (95% CI)** | 28      | 55     | 30    | 55 | 66.7   | 0.93  | [0.65, 1.33] |                               |                               |
| **Total events** | 28      | 30     |       |    |        |       |            |                               |                               |
| Heterogeneity: not applicable |   |        |       |    |        |       |            |                               |                               |
| Test for overall effect: Z = 0.38 (P = 0.70) |   |        |       |    |        |       |            |                               |                               |

Total events: 85

Heterogeneity: ch² = 1.39, df = 1 (P = 0.24); I² = 28%

Test for overall effect: Z = 1.23 (P = 0.22)

Test for subgroup differences: ch² = 1.36, df = 1 (P = 0.24); I² = 26.3%

(b)

| Study or subgroup | AT + TCM + CM | Events | Total | CM | Events | Total | Weight (%) | Risk ratio M-H, fixed, 95% CI | Risk ratio M-H, fixed, 95% CI |
|------------------|---------------|--------|-------|----|--------|-------|------------|-------------------------------|-------------------------------|
| Shen et al, 2017 | 1             | 37     | 2     | 37 | 100.0  | 0.50  | [0.05, 5.28] |                               |                               |
| **Total (95% CI)** | 37             | 37     | 1     | 2  | 100.0  | 0.50  | [0.05, 5.28] |                               |                               |
| **Total events** | 1              | 2      |       |    |        |       |            |                               |                               |
| Heterogeneity: not applicable |   |        |       |    |        |       |            |                               |                               |
| Test for overall effect: Z = 0.58 (P = 0.56) |   |        |       |    |        |       |            |                               |                               |

(c)
Therefore, future research should pay more attention to the above aspects and avoid the risk of prejudice or revise evaluation tools to make them more suitable for acupuncture, Chinese medicine therapy, or other conservative treatment.

4. Discussion

In the current study, we conducted a systematic review and meta-analysis of 14 RCTs with 1593 participants to evaluate the efficacy and safety of acupuncture for PCS. The outcomes assessment of this review are summarized in 3 aspects: the change of pain before and after treatment, the incidence of POVN, and the recovery of gastrointestinal function (first defecation time, 1st flatus time, and 1st bowel sounds time). There were significant differences between acupuncture and CM in the POVN and the recovery of gastrointestinal function. However, acupuncture plus CM with single CM did not show statistical differences in reduction of pain.

When acupuncture was added to CM, our results indicated no significant reductions in pain intensity between CM and CM + acupuncture. A previous study [31] reported no significant difference in pain intensity between acupuncture + CM (tramadol) and CM (tramadol). However, the quality of evidence for this study was “low”; hence, we disputed these results. No significant differences in pain were reported between acupuncture and CM (morphine). However, only one trial [41] evaluated the differences in pain efficacy between acupuncture and CM. Therefore, the results concerning the efficacy of acupuncture as monotherapy for pain reduction in PCS should be interpreted with caution.

Even though the quality of the evidence for the outcome was moderate, 3 studies [34–36] showed significant differences between AT + CM and CM in POVN. No significant differences in efficacy were reported between AT and CM. In addition, AT + TCM + CM showed no significant differences from CM.

In recovery of gastrointestinal function, AT + CM VS CM, AT VS CM, and AT + TCM + CM VS CM showed significant differences. However, this review reported significant differences between acupuncture and CM, and the quality of the evidence for the outcome was moderate. In addition, the results indicated that acupuncture might improve first defecation time and 1st flatus time; however, due to the limited number of studies included, these results require further investigations. The significant differences in efficacy reported between AT + TCM + CM and CM were not conclusive due to the low level of evidence and the limited number of studies included.

Only 4 RCTs (28.57%) reported safety data for acupuncture, and there was no reported evidence of association of acupuncture with any serious adverse events. Therefore, this review could not draw any firm conclusions on the safety of acupuncture for PCS.

This review has several limitations. (1) Despite our efforts to reduce bias and the inclusion of grey literature, we are not...
| Study or subgroup | AT + CM | SD Mean | Total | CM | SD Mean | Total | Weight (%) | Std. Mean difference IV, random, 95% CI | Std. Mean difference IV, random, 95% CI |
|------------------|---------|---------|-------|----|---------|-------|------------|----------------------------------------|----------------------------------------|
|                  | Mean    | SD      |       | Mean| SD      |       |            |                                        |                                        |
| **4.1.1 AM + CM VS CM** |         |         |       |     |         |       |            |                                        |                                        |
| Hou et al, 2018  | 16      | 4.2     | 50    | 32.8| 4.8     | 50    | 14.3       | -3.70 [-4.35, -3.04]                   |                                        |
| **Heterogeneity:** not applicable |         |         |       |     |         |       |            |                                        |                                        |
| **Test for overall effect:** Z = 11.09 (P < 0.00001) |         |         |       |     |         |       |            |                                        |                                        |
| Total (95% CI)  | 325     | 323     | 100.0 |     |         |       | -2.66 [-3.82, -1.50]                   |                                        |
| **4.1.2 MA + CM VS CM** |         |         |       |     |         |       |            |                                        |                                        |
| Hua, 2016       | 37.26   | 5.56    | 30    | 76.38| 5.92    | 30    | 12.5       | -6.72 [-8.07, -5.38]                   |                                        |
| Song, 2017      | 24.23   | 6.25    | 40    | 30.15| 8.62    | 40    | 14.7       | -0.78 [-1.23, -0.32]                   |                                        |
| Wu et al, 2018  | 24.66   | 8.23    | 52    | 49.72| 8.54    | 52    | 14.5       | -2.97 [-3.53, -2.40]                   |                                        |
| **Subtotal (95% CI)** | 122     | 122     | 41.7  |     |         |       | -3.40 [-5.92, -0.88]                   |                                        |
| **Heterogeneity:** tau^2 = 4.77; chi^2 = 86.42, df = 2 (P < 0.00001); I^2 = 98% |         |         |       |     |         |       |            |                                        |                                        |
| **Test for overall effect:** Z = 2.64 (P = 0.008) |         |         |       |     |         |       |            |                                        |                                        |
| **4.1.3 EA + CM VS CM** |         |         |       |     |         |       |            |                                        |                                        |
| Chang et al, 2019 | 22.56  | 4.69    | 45    | 27.01| 5.83    | 45    | 14.7       | -0.83 [-1.27, -0.40]                   |                                        |
| Yang et al, 2018 | 17.88   | 1.21    | 32    | 18.75| 0.48    | 30    | 14.6       | -0.92 [-1.45, -0.40]                   |                                        |
| Wu et al, 2018  | 24.66   | 8.23    | 52    | 49.72| 8.54    | 52    | 14.5       | -2.97 [-3.53, -2.40]                   |                                        |
| **Subtotal (95% CI)** | 77      | 75      | 29.3  |     |         |       | -0.87 [-1.20, -0.54]                   |                                        |
| **Heterogeneity:** tau^2 = 0.00; chi^2 = 0.06, df = 1 (P = 0.80); I^2 = 0% |         |         |       |     |         |       |            |                                        |                                        |
| **Test for overall effect:** Z = 5.11 (P < 0.00001) |         |         |       |     |         |       |            |                                        |                                        |
| **4.1.4 EA + Auricular therapy + CM VS CM** |         |         |       |     |         |       |            |                                        |                                        |
| Liu et al, 2018  | 21.02   | 3.67    | 76    | 35.52| 4.9     | 76    | 14.6       | -3.33 [-3.83, -2.84]                   |                                        |

**Figure 6:** Forest plot of first flatus time: (a) AT + CM vs. CM, (b) AT vs. CM, and (c) AT + TCM + CM vs. CM.
| Study or subgroup | AT + CM VS CM | SDMean | Total | CM SD | Total | Weight (%) | Std. Mean difference | Std. Mean difference |
|------------------|---------------|--------|-------|-------|-------|------------|----------------------|----------------------|
| Weight           |               |        |       |       |       |            | IV, random, 95% CI   | IV, random, 95% CI   |
|                  |               |        |       |       |       |            |                      |                      |
| 5.1.1 EA + CM VS CM |             | 17.04  | 3.15  | 45    | 21.87 | 4.9        | 45 25.4 -1.16 [-1.61, -0.71] |                      |
| Subtotal (95% CI)|               | 45     | 25.4  |       |       |            |                      |                      |
| Heterogeneity: not applicable | |        |       |       |       |            |                      |                      |
| Test for overall effect: Z = 5.08 (P < 0.00001) | |        |       |       |       |            |                      |                      |
| 5.1.2 MA + CM VS CM |             | 13.95  | 2.62  | 30    | 24.68 | 2.99       | 30 24.5 -3.77 [-4.63, -2.91] |                      |
| Subtotal (95% CI)|               | 30     | 24.5  |       |       |            |                      |                      |
| Heterogeneity: not applicable | |        |       |       |       |            |                      |                      |
| Test for overall effect: Z = 8.57 (P < 0.00001) | |        |       |       |       |            |                      |                      |
| 5.1.3 AM + CM VS CM |             | 7.6    | 3.2   | 50    | 24    | 5.1        | 50 25.0 -3.82 [-4.49, -3.15] |                      |
| Subtotal (95% CI)|               | 50     | 25.0  |       |       |            |                      |                      |
| Heterogeneity: not applicable | |        |       |       |       |            |                      |                      |
| Test for overall effect: Z = 11.22 (P < 0.00001) | |        |       |       |       |            |                      |                      |
| 5.1.4 EA + Auricular therapy + CM VS CM |             | 17.23  | 1.98  | 76    | 31.77 | 3.67       | 76 25.1 -4.91 [-5.55, -4.26] |                      |
| Subtotal (95% CI)|               | 76     | 25.1  |       |       |            |                      |                      |
| Heterogeneity: not applicable | |        |       |       |       |            |                      |                      |
| Test for overall effect: Z = 14.96 (P < 0.00001) | |        |       |       |       |            |                      |                      |

| Study or subgroup | AT + TCM + CM VS CM | SDMean | Total | CM SD | Total | Weight (%) | Std. Mean difference | Std. Mean difference |
|------------------|---------------------|--------|-------|-------|-------|------------|----------------------|----------------------|
| Weight           |                      |        |       |       |       |            | IV, fixed, 95% CI    | IV, fixed, 95% CI    |
|                  |                      |        |       |       |       |            |                      |                      |
| 5.2.1 EA + TCM + CM VS CM |             | 18.31  | 3.71  | 275   | 29.39 | 3.69       | 112 81.1 -2.98 [-3.28, -2.67] |                      |
| Subtotal (95% CI)|               | 275    | 81.1  |       |       |            |                      |                      |
| Heterogeneity: not applicable | |        |       |       |       |            |                      |                      |
| Test for overall effect: Z = 19.16 (P < 0.00001) | |        |       |       |       |            |                      |                      |
| 5.2.2 AM + TCM + CM VS CM |             | 21.3   | 3.1   | 37    | 32.2  | 4.6        | 37 18.9 -2.63 [-3.26, -2.00] |                      |
| Subtotal (95% CI)|               | 37     | 18.9  |       |       |            |                      |                      |
| Heterogeneity: not applicable | |        |       |       |       |            |                      |                      |
| Test for overall effect: Z = 8.18 (P < 0.00001) | |        |       |       |       |            |                      |                      |

**Figure 7:** Forest plot of first bowel sounds time: (a) AT + CM vs. CM and (b) AT + TCM + CM vs. CM.

**Table 5:** Adverse events in included studies.

| Study (reference) | Sample size (A)/(B) | (A) Treatment group | (B) Control group | Adverse events |
|-------------------|---------------------|---------------------|-------------------|----------------|
| Liu and Zhang 2013 [37] | 55/55               | MA                  | CM (ondansetron)  | B: 2 cases of dizziness, 3 cases with constipation, and 13 cases with extrapyramidal symptoms |
| Shen 2014 [39] | 57/57               | MA + (B)            | CM (Metoclopramide) | A: 1 case of dizziness, B: 3 cases of dizziness, 1 case with constipation, and 2 cases with extrapyramidal symptoms |
| Jing 2017 [40] | 40/40               | MA + (B)            | CM                | None |
| Xiao 2012 [43] | 60/60               | MA                  | (Fentanyl and morphine) | A: 1 case of dizziness, B: 25 cases of PONV and 2 cases with hypotension |
# Table 6: Full-text articles excluded with reasons.

| Full-text articles excluded | Reasons |
|-----------------------------|---------|
| Cai 2018¹                  | Non-RCT |
| Pan 2017²                  | Non-RCT |
| Wang 2019³                 | Non-RCT |
| Shen et al. 2002⁴          | Not acupuncture |
| Zhang et al. 2012⁵          | Not acupuncture |

References: ¹Cai C. Clinical observation on the effect of warm acupuncture on the recovery of gastrointestinal function after cholecystectomy. Chinese and Foreign Medical Research. 2018; 16 (25):34–36. ²Pan D. Clinical observation on the recovery of gastrointestinal function after laparoscopic cholecystectomy in 60 patients with acupuncture. For All Health. 2017; 11 (10):165-166. ³Wang C. Effects of acupuncture at Zusanli and Hegu on gastrointestinal dysfunction after gallbladder stones. Xinjiang Medical University; 2019. ⁴Shen P, Xu Y, Jiang W, et al. Clinical study on acupoint electrical stimulation to promote recovery of gastrointestinal function after operation-- A clinical data of 30 cases. Jiangsu Journal of Traditional Chinese Medicine. 2002; 23 (7):33-34. ⁵Zhang F, Li S, Li N. Effect of acupoint pulse electrical stimulation on intestinal function recovery after cholecystectomy. Today Nurse. 2012; 12:29-30.

# Table 7: The PRISMA checklist about this SR.

| Section/topic                  | # | Checklist item                                                                 | Reported on page # |
|-------------------------------|---|-------------------------------------------------------------------------------|--------------------|
| Title                         | 1 | Identify the report as a systematic review, meta-analysis, or both             | 1                  |
| Abstract                      | 2 | Provide a structured summary including, as applicable, background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; and systematic review registration number | 1                  |
| Structured summary            | 3 | Describe the rationale for the review in the context of what is already known | 2                  |
| Introduction                  | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS) | 2                  |
| Introduction Rationale        | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number | 2                  |
| Objectives                    | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, and publication status) used as criteria for eligibility, giving rationale | 3                  |
| Methods                       | 7 | Describe all information sources (e.g., databases with dates of coverage and contact with study authors to identify additional studies) in the search and date last searched such that it could be repeated. | 2-3                |
| Protocol and registration     | 8 | Present full electronic search strategy for at least one database, including any limits used, | 2                  |
| Information sources           | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | 3                  |
| Search                        | 10| Describe method of data extraction from reports (e.g., piloted forms, independently, and in duplicate) and any processes for obtaining and confirming data from investigators | 3-4                |
| Study selection               | 11| List and define all variables for which data were sought (e.g., PICOS and funding sources) and any assumptions and simplifications made | 3-4                |
| Data items                    | 12| Review methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | 4                  |
| Risk of bias in individual studies | 13| State the principal summary measures (e.g., risk ratio and difference in means) | 4                  |
| Summary measures              | 14| Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis | 4                  |
| Synthesis of results          | 15| Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias and selective reporting within studies) | 4                  |
| Risk of bias across studies   | 16| Describe methods of additional analyses (e.g., sensitivity or subgroup analyses and meta-regression), if done, indicating which were prespecified | 4                  |
| Additional analyses           | 17| Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | 4                  |
| Results                       | 18| For each study, present characteristics for which data were extracted (e.g., study size, PICOS, and follow-up period) and provide the citations | 4-5                |
sue that all studies were included. (2) The number of selected studies and the sample size in most of the studies were small. (3) The low methodological quality of some RCTs remains a challenge. However, many studies showed performance bias since acupuncture was difficult to blind. The low methodological quality of some RCTs may cause overestimation of the effects of acupuncture on PCS. (4) In some studies, significant heterogeneity was reported for several outcomes. These may have been caused by a number of factors such as age, gender, and surgical methods among other factors of the recruited PCS patients. In addition, acupuncture clinical trials involve many factors that may lead to heterogeneity, such as acupoint selection, depth of insertion, deqi, needle stimulation, needle retention duration, number of treatment sessions, frequency of treatment, and duration. Even though the treatment method used in the control group is CM, the differences in dosage and dosage forms may have caused heterogeneity. (5) The quality of various outcomes evidence included mainly low and moderate quality evidence. Therefore, future research may have a significant impact on existing evidence and may change the evaluation results.

We provide prospects and suggestions for future research. Previous research reveals that PCS lacks a widely accepted diagnostic standard. Future research must standardize and generalize acupuncture treatment for PCS. It is important to consider possible clinical heterogeneity due to inconsistencies in the types of acupuncture, acupoint selection, acupuncture retention time, stimulation intensity, and course. In this review, most of the included studies used the ST 36 and PC 6 acupoints. The most frequent needle retention time was 30 minutes, and the number of treatments was 6 times. The treatment time was once a day. According to the current RCTs included in this review, the methodological quality and evidence quality was not high. Therefore, in future, a multicentered, large sample, high quality RCT should be conducted in full compliance with the Consolidated Standards of Reporting Trials (CONSORT) [46], Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) [47], and Cochrane Handbook for Systematic Reviews of Interventions to control the methodological quality.

5. Conclusion
The results of this SR/MA indicated that acupuncture may improve the overall symptoms of PCS. The reported acupuncture-related adverse events are mild and acceptable. However, due to limited data, heterogeneity of acupuncture methods among the RCTs and the low methodological quality of some of the RCTs, there is a need for additional and well-designed RCTs with larger sample sizes to be performed to confirm these results.

Appendix

(A). Full-Text Articles Excluded with Reasons
Full-text articles excluded with reasons are given in Table 6.

(B). PRISMA-2009 Checklist
PRISMA-2009 checklist is given in Table 7.

Data Availability
No data were used to support this study.

Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
ZY, QX, and GX contributed equally to this work. ZY, YC, and FL conceived this study. ZY, QX, and GX developed the study and implemented the systematic review under the supervision of JC and LZ. ZY and GX provided the statistical analysis plan of the study and conducted data analysis. QX and HY performed the study search, screening, and extraction of data, whereas YF and JZ reviewed the work. ZY, QX, and GX wrote the first manuscript draft, and all authors gave input to the final draft of the manuscript. LZ and FL supervised the study and critically reviewed the paper.

Acknowledgments
This work was financially supported by the National Key Research and Development Program of China (no. 2019YFC1709700), the National Natural Science Foundation of China (nos. 81590951, 81722050, and 81973961), and the Project of Science and Technology Department of Sichuan Province (20ZDYF1199 and 2019YS00081).

References
[1] A. Zahedian, S. K. Ahangar, and Y. Asghari, “Post cholecystectomy syndrome need to redo laparoscopic completion surgery: a case report,” International Journal of Surgery Case Reports, vol. 42, pp. 145–147, 2018.
[2] S. A. Ahrendt and H. A. Pitt, “Biliary tract,” in Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, C. M. Townsend, R. D. Beauchamp, B. M. Evers, and K. L. Mattox, Eds., Elsevier, Philadelphia, PA, USA, 17th edition, 2004.
[3] D. Arora, R. Kausik, R. Kaur, and A. Sachdev, “Post-cholecystectomy syndrome: a new look at an old problem,” Journal of Minimal Access Surgery, vol. 14, no. 3, pp. 202–207, 2018.
[4] R. Zackria, and A. Wahed, Postcholecystectomy Syndrome, StatPearls, Treasure Island, FL, USA, 2020.
[5] H. Kim, I. W. Han, J. S. Heo, C. Y. Lim, Y. S. Choi, and S. E. Lee, “Postcholecystectomy syndrome: symptom clusters after laparoscopic cholecystectomy,” Annals of Surgical Treatment and Research, vol. 95, no. 3, pp. 135–140, 2018.
[6] D. F. Oh, M. T. Rotelli, and N. Palasciano, “Diet after cholecystectomy,” Current Medicinal Chemistry, vol. 26, no. 19, pp. 3662–3665, 2019.
[7] T. Moore and M. Amin, “Post-cholecystectomy syndrome,” Clinical Practice and Cases in Emergency Medicine, vol. 1, no. 4, pp. 446–447, 2018.
[8] B. H. Shirah, H. A. Shirah, S. H. Zafar, and K. B. Albeladi, “Clinical patterns of postcholecystectomy syndrome,” Annals of Hepato-Biliary-Pancreatic Surgery, vol. 22, no. 19, pp. 52–57, 2018.
[9] S. S. Jawnoo, S. Mohandas, and L. M. Almond, “Postcholecystectomy syndrome (PCS),” International Journal of Surgery, vol. 8, no. 1, pp. 15–17, 2010.
[10] N. Ažh, I. P. Kudrevatyykh, and A. F. Shul’ga, “Postkholetsitëktomicheskii sindrom [The postcholecystectomy syndrome],” Vestnik Hirurgii Im. I.I. Grekova, vol. 150, no. 1–2, pp. 20–23, 1993.
[11] M. A. Sahmeddini and A. Fazelzadeh, “Does auricular acupuncture reduce postoperative vomiting after cholecystectomy?” The Journal of Alternative and Complementary Medicine, vol. 14, no. 10, pp. 1275–1279, 2008.
[12] F. Y. Wen, S. C. Li, and G. M. Wang, “Effects of acupuncture of Jianjing (GB 21) on gallbladder volume and symptoms of cholecystitis patients,” Zhongguo Yi Xue Ke Xue Yuan Yi Xue Ying Biao Yan Jiu Suo Bian Ji], vol. 37, no. 5, pp. 398–402, 2012.
[13] T. Liu and C. Liu, “Clinical experience of acupuncture and moxibustion for treatment of chronic cholecystitis,” Zhonghua Zhen Jin Zhi, vol. 25, no. 10, pp. 737–739, 2005.
[14] S. Zhou, “Thirty cases of chronic cholecystitis treated by acupuncture and oral administration of da chai hu tang,” Journal of Traditional Chinese Medicine, vol. 28, no. 3, pp. 173–174, 2008.
[15] A. J. Vickers, E. A. Vertosick, G. H. Lewith et al., “Acupuncture for chronic pain: update of an individual patient data meta-analysis,” The Journal of Pain, vol. 19, no. 5, pp. 455–474, 2018.
[16] L. MacPherson, J. Chen, Y. X. Li et al., “The long-term effect of acupuncture for migraine prophylaxis,” JAMA Internal Medicine, vol. 177, no. 4, pp. 508–515, 2017.
[17] L. Zhao, D. Li, H. Zheng et al., “Acupuncture as adjunctive therapy for chronic stable Angina,” JAMA Internal Medicine, vol. 179, no. 10, 1388 pages, Article ID e192407, 2019.
[18] A. Lee, S. K. Chan, and L. T. Fan, “Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting,” Cochrane Database of Systematic Reviews, vol. 11, no. 11, Article ID CD003281, 2015.
[19] H. C. Shin, J. S. Kim, S. K. Lee et al., “The effect of acupuncture on postoperative nausea and vomiting after pediatric tonsillectomy: a meta-analysis and systematic review,” The Laryngoscope, vol. 126, no. 8, pp. 1761–1767, 2016.
[20] H. Kwon, T. He, and Q. Xu, “Acupuncture and regulation of gastrointestinal function,” World Journal of Gastroenterology, vol. 21, no. 27, pp. 8304–8313, 2015.
[21] L. Lan, F. Zeng, G. J. Liu, L. Ying, X. Wu, and L. M. Liu, “Acupuncture for functional dyspepsia,” Cochrane Database of Systematic Reviews, vol. 10, Article ID CD008487, 2014.
[22] G. H. Guyatt, A. D. Oxman, H. J. Schünemann, P. Rugwell, and A. Knottnerus, “Grade guidelines: a new series of articles in the journal of clinical epidemiology,” Journal of Clinical Epidemiology, vol. 64, no. 4, pp. 380–382, 2011.
[23] Z. Yin, Y. Cheng, and Q. Xiao, “Acupuncture for the postcholecystectomy syndrome: protocol for a systematic review and meta-analysis,” Medicine (Baltimore), vol. 98, no. 32, Article ID e16769, 2019.
[24] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” British Medical Journal, vol. 339, Article ID b2535, 2009.
[25] D. Kang, Y. Wu, D. Hu, Q. Hong, J. Wang, and X. Zhang, “Reliability and external validity of AMSTAR in assessing quality of TCM systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 732195, 7 pages, 2012.
[26] Y. He, X. Guo, B. H. May et al., “Clinical evidence for association of acupuncture and acupressure with improved cancer pain: a systematic review and meta-analysis,” JAMA Oncology, vol. 6, no. 2, p. 271, 2020.
[27] Y. Yao, Q. Zhao, C. Gong et al., “Transcutaneous electrical acupoint stimulation improves the postoperative quality of recovery and analgesia after gynecological laparoscopic surgery: a randomized controlled trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 324360, 6 pages, 2015.
[28] Y. Liu, B. H. May, A. L. Zhang et al., “Acupuncture and related therapies for treatment of postoperative ileus in colorectal cancer: a systematic review and meta-analysis of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 3178472, 18 pages, 2018.

[29] K. D. Checchi, K. F. Huybrechts, J. Avorn, and A. S. Kesselheim, “Electronic medication packaging devices and medication adherence,” Journal of the American Medical Association, vol. 312, no. 12, pp. 1237–1247, 2014.

[30] J. Yang, J. Chen, M Yang et al., “Acupuncture for hypertension,” The Cochrane Database of Systematic Reviews, vol. 11, no. 11, Article ID CD008821, 2018.

[31] V. Erden, A. S. Yıldız, and C. Güler, “Postoperative analgesic effect of acupuncture in laparoscopic cholecystectomy surgery,” Ağrı — The Journal of The Turkish Society of Algology, vol. 27, no. 3, pp. 155–159, 2015.

[32] J. Chang, Z. Xu, and Z. Wang, “Effect of electroacupuncture stimulation on gastric motility in patients undergoing laparoscopic cholecystectomy,” Global Traditional Chinese Medicine, vol. 12, no. 12, pp. 1875–1877, 2019.

[33] C. Cui, “Effect of Jiawei Xiaochengqi Decoction combined with acupuncture on gastrointestinal function recovery after laparoscopic cholecystectomy,” Yi Xue Li Lun Yu Shi Jian, vol. 16, no. 2, 2006.

[34] H. Xiaojian, “Effect of electroacupuncture combined with ear acupuncture on recovery after laparoscopic cholecystectomy,” Journal of Changchun University of Chinese Medicine, vol. 34, no. 2, pp. 312–314, 2018.

[35] H. Shangbo, Beneficial Effects of Acupuncture Intervention on Gastrointestinal Function Recovery of Patients after Laparoscopic Cholecystectomy, Nanjing University of Chinese Medicine, Nanjing, China, 2016.

[36] L. Hui, “Effects of electroacupuncture combined with ear acupuncture on recovery after laparoscopic cholecystectomy,” Journal of Shaanxi University of Chinese Medicine, vol. 41, no. 4, pp. 90–92, 2018.

[37] J. Liu and W. Zhang, “Acupuncture for 55 cases of vomiting after laparoscopic cholecystectomy,” Shaanxi Journal of Traditional Chinese Medicine, vol. 4, 2013.

[38] T. Shen, “Effects of acupuncture and Chinese herbal hot compression on gastrointestinal function recovery after laparoscopic cholecystectomy,” Henan Journal of Surgery, vol. 23, no. 6, pp. 115–116, 2017.

[39] W. Shen, “57 cases of vomiting after laparoscopic cholecystectomy with metoclopramide and acupuncture,” Western Journal of Chinese Medicine, vol. 27, no. 8, 2014.

[40] S. Jing, Effect of Acupuncture Stimulation of Acupoints and Reflex Areas on the Recovery of Gastrointestinal Function in Patients after Laparoscopic Cholecystectomy, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 2017.

[41] J. Wang, “Comparative study of the effects of electroacupuncture and morphine intravenously controlled analgesia on postoperative recovery in patients undergoing laparoscopic cholecystectomy,” Shanghai Journal of Traditional Chinese Medicine, vol. 50, no. 9, pp. 52–56, 2016.

[42] W. U. Xiaobing and W. Jiahe, “Effect of moxibustion at Zusanli combined with abdominal acupuncture on gastrointestinal function after laparoscopic cholecystectomy,” Jilin Journal of Traditional Chinese Medicine, vol. 38, no. 12, pp. 1464–1467, 2018.

[43] G. Xiao, “Observation on the effect of acupuncture on analgesia after laparoscopic cholecystectomy,” Shaanxi Journal of Traditional Chinese Medicine, vol. 33, no. 5, 2012.